問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Tri-Service General Hospital

List

851Cases

2023-06-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
19Sites

Recruiting19Sites

2021-04-01 - 2029-09-01

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

  • Condition/Disease

    Follicular Lymphoma

  • Test Drug

    懸液用粉劑

Participate Sites
9Sites

Recruiting9Sites

2020-10-15 - 2027-09-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2021-12-01 - 2024-06-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

-

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

2025-07-18 - 2029-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-03-01 - 2030-09-20

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2010-07-01 - 2011-07-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2003-06-01 - 2006-06-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

2019-08-19 - 2024-04-30

Phase III

Completed
A 12-week phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once monthly subcutaneous erenumab 70 mg in adult chronic migraine patients

  • Condition/Disease

    Chronic Migraine

  • Test Drug

    AMG334 (erenumab)

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

林剛旭
China Medical University Hospital

1 25 26 27 28 29 86
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB